Discover and read the best of Twitter Threads about #wclc19
Most recents (6)
#OncoAlert Exploration of the impact of #EGFR TKIs on the #TME @CCR_AACR. Analysis of 138 patients with EGFR+ #NSCLC who received a 1st gen EGFR TKI and had pre/post biopsies. Assayed changes in PD-L1 expression, TIL density and TME makeup. #LCSM
clincancerres.aacrjournals.org/content/early/…
clincancerres.aacrjournals.org/content/early/…
@CCR_AACR In general, samples taken post 1st gen TKI had higher PDL1 expression but induction of strong PDL1 expression accompanied by increase in Treg density and CD73 expression. Understanding the TME will allow us to unlock IO benefit (and explain the toxicity when IO precedes TKI). 
@CCR_AACR PDL1 upregulation more common in context of T790M negative resistance. Interestingly, potentially different impact when osimertinib given (no CD73 upregulation). Does our choice of EGFR TKI impact potential efficacy of IO therapy in the future? So many variables to consider!
#WCLC19 Potential target is mesothelin, enriches in advanced disease and #KRAS #NSCLC - note the antigen heterogeneity though. Challenge in CAR-T strategies. Preclinically, dependent on antigen density. In trials though, responses also seen with low expression. #OncoAlert
#WCLC19 Three year update on KEYNOTE-024 by Martin Reck for first line pembro in #NSCLC PDL1 > 50%. 65% crossover rate. OS HR 0.65 and median OS 26.3 months. #OncoAlert #LCSM
#WCLC19 Good outcomes for those patients who complete 2y of pembro on KN-024. And safety profile overall more favorable than chemo. Reassuring to see continued long term benefit. Appreciate the updates on these practice changing trials. #OncoAlert
#WCLC19 For those who did relapse after stopping pembro, rechallenge is an option. DCR 70%. Does not confirm optimal treatment duration, an ongoing important question, but reassuring! #OncoAlert #LCSM
#WCLC19 Registrational results for LOXO-292, now Selpercatinib, presented by @alexdrilon. This is a highly selective RET inhibitor with preclinical CNS activity. Enrolled remarkably quickly: 253 RET+ #NSCLC enrolled since May 2017! #OncoAlert #LCSM
#WCLC19 Selpercatinib patient demographics. Incredible waterfall plot! In previously treated ORR 68% and nearly all patients with some reduction. CNS ORR 91%. Even better in 1L: 85%! mPFS 18.4 months. Impressive results for #RET #NSCLC #OncoAlert
#WCLC19 Illustrative examples of the depth of response possible. Safety profile very reassuring. Impressive results from Selpercatinib - now awaiting update from BLU-667. A great time for #RET targeting! #OncoAlert #LCSM #PrecisionMedicine
#WCLC19 Highly anticipated update on AMG510 in #KRAS #NSCLC by Ramaswamy Govindan does not disappoint. High RR (48%, 54% at 960mg) and DCR of 100%! No DLTs! Amazing early data in a huge area of need. #OncoAlert
#WCLC19 Swimmers plot for AMG510 shown here. Responses occur quickly. NOTE: not all of these responses are confirmed. Need to see how durable these are. Remember our experience with MEKi in #KRAS #NSCLC - RR nice but not durable (trametinib plot shown) #OncoAlert
#WCLC19 @rdoebele kicks off the plenary with a discussion of tumor agnostic therapy. Really refers to biology driven. Our current siloed approach to oncology is a bit of a barrier to this strategy. Timing favored lung cancer as the field where this became mainstream. #OncoAlert
#NTRK is a great example where we see efficacy across tumors and no indication of a specific tumor type resistant to inhibition. But we see similar themes in #ALK and #ROS1 - will there be a regulatory path forward? #OncoAlert #WCLC19
Importantly, resistance also seems to be tumor agnostic. Similar mutations seen mediating resistance across tumor types. Predicting #NRG1 as next important target across tumor types. Biology is more dependent on the genomics than the histology! #WCLC19 #OncoAlert
